Gilteritinib + daunorubicin + cytarabine for Acute myeloid leukaemia (AML) [TSID12331]

Status:

Topic prioritisation

Technology type:

Medicine

Decision:

Awaiting decision

For further information on how we select topics for development, please see our page about topic prioritisation